Active Clinical Studies at Retina Consultants of Western New York

Retina Consultants of Western New York strives to educate and treat our patients with precision, confidence and dedication. With these three ideals in mind we actively participate in clinical studies that we feel further the care of our patients. The following, lists our active clinical studies, as well as upcoming studies.

Active Studies:

  1.  DRCR (Proliferative Diabetic Retinopathy)
  2.  Regeneron (Diabetic Macular Edema)
  3.  Regeneron (Branch Retinal Vein Occlusion)
  4.  Santen (Uveitis)

 

1.  Sponsor:

Diabetic Retinopathy Clinical Research Network (DRCR)

Principal Investigator:

Dr. Paul Lee

Clinical Trial Title:

Protocol N

An Evaluation of Intravitreal Ranibizumab (Lucentis) for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy

Synopsis:

To evaluate intravitreal ranibizumab (Lucentis) as treatment for vitreous hemorrhage from proliferative diabetic retinopathy in order to avoid vitrectomy.

NOT CURRENTLY ENROLLING

 

2. Sponsor:

Regeneron Pharmaceuticals Inc.

Principal Investigator:

Dr. Paul Lee

 

Clinical Trial Title:

VGFT-OD-1009

A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema

 

Synopsis:

To assess the efficacy and safety of intravitreal (IVT) administration of vascular endothelial growth factor (VEGF) Trap-Eye compared to laser treatment in improving best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME).

NOT CURRENTLY ENROLLING

 

3. Sponsor:

Regeneron Pharmaceuticals Inc.

Principal Investigator:

Dr. Mehdi Khan

Clinical Trial Title:

VGFTe-RVO-1027

A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Synopsis:

To assess the efficacy and safety of intravitreal (IVT) administration of vascular endothelial growth factor (VEGF) Trap-Eye in improving best corrected visual acuity (BCVA), compared to laser treatment, in patients with macular edema secondary to branch retinal vein occlusion (BRVO).

4. Sponsor:

Santen Inc.

Principal Investigator:

Dr. Ramakrishna Ratnakaram

 

Clinical Trial Title:

Santen 32-007

A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye

 

Synopsis:

To evaluate the safety and efficacy of intravitreal injections of DE-109 (44ug, 440ug, 880ug) for the treatment of active, non-infectious uveitis of the posterior segment of the eye.

Posted in Uncategorized | Tagged , , , | Leave a comment

Ophthalmologists Experience Visual Maladies To Improve Care For Patients

Buffalo, NY –  Olmstead Center for Sight held a unique exercise to help physicians provide better care for their Patients.

Our own Dr Lee, Dr Koreishi and Dr Ram were present at this exercise — see the news cast and complete details here.

http://www.wgrz.com/news/local/story.aspx?storyid=95873&catid=37

Posted in Uncategorized | Leave a comment

Dr. Ratnakaram joins Retina Consultants of WNY

Retina Consultants of Western New York, P.C. physician partners Faruk M. Koreishi, M.D., Paul J. Lee, M.D., Mehdi A. Khan, D.O., Christopher M. Jermak, M.D. are pleased to announce the addition of Ramakrishna (Ram) Ratnakaram, O.D., M.D. to our staff.

Dr. Ratnakaram was a tenured Associate Professor of Ophthalmology at the University of Florida College of Medicine, Gainesville, Florida until joining our practice. There he served as Director of Vitreo-Retinal Surgery & Fellowship training and as Medical Director of the eye clinics. During his time at the University, he published many papers and posters. He was the principle investigator in multiple clinical trials and is the lead surgeon in the NIH gene therapy research project

Dr. Ratnakaram obtained his first professional degree, Doctor of Optometry, from the University of Houston College of Optometry. Later he received his medical degree from Ross University School of Medicine. He completed his residency in Ophthalmology at UMDNJ-New Jersey Medical Scholl and received the Alfonse Cinnotti Award for Clinical Excellence. He later attended Tulane University College of Medicine for fellowship training in Vitreo-Retinal Surgery, diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, retinal laser procedures and other retinal diseases and treatments. Dr. Ratnakaram is board certified in Ophthalmology.

Dr. Ratnakaram is seeing patients at all three of our locations (Williamsville, Orchard Park and Niagara Falls). Please call (716) 795-2040 to schedule an appointment.

Posted in Uncategorized | Tagged , , , , , | Leave a comment

Welcome to Retina Consultants of Western New York

Under the direction and expertise of Doctors Faruk Koreishi, Paul Lee, Christopher Jermak, Mehdi Khan and Dr.Ramakrishna Ratnakaram our practice has become WNY’s largest Retina Practice. We specialize in the diagnosis and treatment of diseases of the retina and vitreous of eye by means of Medical and Surgical Management.  One of our main areas of focus is Macular Degeneration/Diabetic Retinopathy.

We are proud to be such a significant part of the area’s health community. Our vision is to provide the best medical treatment possible and to work closely with your referring physician or optometrist to provide the highest quality eye care.

Over the following months our lectures and seminar notes as well as articles from our physicians will be posted here as well as current educational resources and information.

In the mean time please visit our website:

http://www.wnyretina.com

Posted in Uncategorized | Leave a comment